Abstract
Background Women with hereditary breast and ovarian cancer (HBOC) have an estimated 15-65% lifetime risk of ovarian cancer; similarly, women with Lynch syndrome have a 40-60% lifetime risk of endometrial cancer and a 10-12% lifetime risk of ovarian cancer. The aim of this study was to investigate the impact of genetic testing on risk-reducing behavior for gynecologic malignancies in women being tested for HBOC and Lynch syndrome.
Highlights
Women with hereditary breast and ovarian cancer (HBOC) have an estimated 15-65% lifetime risk of ovarian cancer; women with Lynch syndrome have a 40-60% lifetime risk of endometrial cancer and a 10-12% lifetime risk of ovarian cancer
Women evaluated for HBOC were tested for germline BRCAI or BRCA2 gene mutations; those evaluated for Lynch syndrome were tested for germline DNA mismatch repair (MMR) gene mutations
40% (34/84) of subjects being tested for HBOC and 46% (26/57) of those tested for Lynch syndrome reported prior gynecologic cancer screening
Summary
The aim of this study was to investigate the impact of genetic testing on risk-reducing behavior for gynecologic malignancies in women being tested for HBOC and Lynch syndrome
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
